Skip to main content
05 Feb 2024


ReGEN Biomedical and Demcon Announce New Partnership

Demcon and ReGEN Biomedical announce a collaboration, with Demcon becoming a shareholder. This partnership not only promises growth and innovation for both parties but also contributes to strengthening the regenerative medicine sector as a whole and achieving the common goal within RegMed XB: expediting the market entry of the latest therapies for chronically ill patients.

The collaboration between Demcon and ReGEN Biomedical, within the framework of the RegMed XB pilot factory, exemplifies the power of public-private partnerships. It is a promising step towards sustainable profitability, aligning with the objectives of the National Growth Fund. We look forward to the positive outcomes of this collaboration!

ReGEN Biomedical, along with the Smart Biomaterials Consortium, LUMC, NecstGen, and ICAT, forms the RegMed XB Pilot Factory. The Pilot Factory brings together all the expertise and infrastructure necessary to bring regenerative medicine solutions to the market and is co-funded by the National Growth Fund, which invests €20 billion in projects for long-term economic growth between 2021 and 2025

To learn more about this exciting collaboration and its potential impact, please read the full press release.

Have something to share?

Now you can contribute to keep our news section fresh and up-to date with relevant events and grants, research results and high impact publications related to REGMED XB’ Moonshots. Contributions can be sent to This email address is being protected from spambots. You need JavaScript enabled to view it.. Please submit the text in English and include a short title. We are looking forward to your input!